Leaders from the Zhongguancun Administrative Committee paid a visit to Minhai Biotechnology for an inspection and study tour.

Release date:

2019-04-26

Author:

Contributed by the General Office

Source:


Abstract

On the afternoon of April 26, 2019, a delegation led by Zhai Lixin, Director of the Zhongguancun Administrative Committee of Beijing, accompanied by He Rui, Member of the Standing Committee of the Daxing District CPC Committee and Deputy District Mayor, and Tian Dexiang, Secretary of the Party Working Committee of the Daxing District Biomedical Base, paid a visit to Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio). The company’s General Manager Zheng Haifa, Executive Deputy General Manager Liu Jiankai, Deputy General Manager Xiao Qiyu, and other relevant leaders joined the delegation on the inspection tour.

  On the afternoon of April 26, 2019, a delegation led by Zhai Lixin, Director of the Zhongguancun Administrative Committee of Beijing, accompanied by He Rui, Member of the Standing Committee of the Daxing District CPC Committee and Deputy District Mayor, and Tian Dexiang, Secretary of the Party Working Committee of the Daxing District Biomedical Base, paid a visit to Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio). The delegation was joined by Zheng Haifa, General Manager of Minhai Bio, Liu Jiankai, Executive Deputy General Manager, Xiao Qiyu, Deputy General Manager, and other relevant company leaders.

 

 

  General Manager Zheng accompanied Director Zhai and other leaders on a tour of the company’s newly constructed R&D and production building. He briefed them on the facility’s key products, including the Sabin‑strain inactivated poliovirus vaccine, the 13‑valent pneumococcal conjugate vaccine, and the lyophilized human rabies vaccine, as well as on the workshop’s layout and overall production capacity. They also engaged in discussions and exchanges regarding high‑quality development models for the vaccine industry.

 

 

  Following the visit, Director Zhai highly commended Minhai Bio’s development, fully recognizing its leading position in the biopharmaceutical vaccine industry. He encouraged the company to continue expanding and strengthening itself, to remain at the forefront of the sector, and offered on-the-spot solutions to address current challenges such as employee household registration and children’s education. In response, General Manager Zheng stated that Minhai Bio’s achievements have been made possible by the substantial support and safeguards provided over the years by the Biomedical Base, and pledged to pursue continuous innovation in future operations, enhance the company’s core competitiveness, and make even greater contributions to the economic development of Daxing District. Finally, on behalf of the company and all its employees, General Manager Zheng expressed gratitude to the Beijing Zhongguancun Administrative Committee for its longstanding care and support.

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09